Search

Displaying results 2601 - 2610 of 5451 in total
  1. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    Aficamten is a cardiac myosin inhibitor. Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symp...

  2. Drug

    Fimasartan

    go.drugbank.com/drugs/DB09279
    Investigational

    It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials.

    Products: KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MG, KANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG
  3. Drug

    Pipotiazine

    go.drugbank.com/drugs/DB01621
    ApprovedInvestigationalWithdrawn

    However, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. … Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics.

    Products: TRIPIPOT® SOLUCIÓN INYECTABLE 25 MG/ML, PIPOTAZ®25 MG/ ML SOLUCION INYECTABLE
  4. Drug

    Sulisobenzone

    go.drugbank.com/drugs/DB11185
    Approved

    It works to filter out both UVA and UVB rays, protecting the skin from sun UV damage [L2153]. … Sulisobenzone is approved by the FDA in concentrations of up to 10% and in Canada, is approved by Health Canada at the same concentrations [F38].

  5. Drug

    Hydroxychloroquine

    go.drugbank.com/drugs/DB01611
    ApprovedInvestigational

    [L8072] It was developed during World War II as a derivative of [quinacrine] with less severe side effects. … [L8072] It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus.

    Products: ARTROQUIN 400 MG, ARTROQUIN 200 MG
  6. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    [L51888] In October of 20225, it was approved for myeloid leukemia patients with nucleophosmin 1 (NPM1) mutations. [L54376] … It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval.

  7. Drug

    Telotristat ethyl

    go.drugbank.com/drugs/DB12095
    Approved

    [A252947] The most common peptides and amines secreted by NET are histamines, tachykinins, kallikrein, and serotonin. … [L43342] It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.

  8. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. … Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes.

  9. Drug

    Norethindrone enanthate

    go.drugbank.com/drugs/DB14678
    Investigational

    Mixtures: MESIGYNA 5 MG+50 MG/1 ML ENJEKSIYONLUK COZELTI ICEREN KULLANIMA HAZIR ENJEKTÖRProducts: DEPOCON INJECTION 200 mg/ml
  10. Drug

    Exametazime

    go.drugbank.com/drugs/DB11179
    Approved

    It acts as a chelating agent for the radioisotope technetium-99m to form a cationic complex. … It is used in the detection of altered regional cerebral perfusion and for the radiolabeling of autologous leukocytes.

    Products: CERETEC FOR INJECTION 0.5 mg/vial